PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Actinium Pharmaceuticals, Inc. (ATNM)
1.780.01 (-0.56%)
1.75 - 1.81
1.03 - 2.41
122.5K / 296.7K (Avg.)
-1.36 | -1.31
These metrics indicate whether the stock trades cheaply or expensively relative to its fundamentals. Value investors use them to find mispricings—buying stocks that appear undervalued, with solid long-term prospects and limited downside risk.
-6.58
Negative P/E while Biotechnology median is -8.55. Seth Klarman would scrutinize path to profitability versus peers.
225.11
P/S exceeding 1.5x Biotechnology median of 12.75. Jim Chanos would check for potential multiple compression risks.
1.98
P/B less than half the Biotechnology median of 4.00. Joel Greenblatt would investigate if assets are truly impaired. Check ROE versus peers.
-24.80
Negative FCF while Biotechnology median P/FCF is -37.22. Seth Klarman would investigate cash flow improvement potential.
-24.82
Negative operating cash flow while Biotechnology median P/OCF is -38.02. Seth Klarman would investigate operational improvement potential.
1.98
Fair value ratio less than half the Biotechnology median of 4.03. Joel Greenblatt would investigate if this discount is justified.
-3.80%
Negative earnings while Biotechnology median yield is -1.91%. Seth Klarman would investigate path to profitability.
-4.03%
Negative FCF while Biotechnology median yield is -1.62%. Seth Klarman would investigate cash flow improvement potential.